Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Other Accumulated Expenses (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Other Accumulated Expenses for 7 consecutive years, with $212000.0 as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Other Accumulated Expenses rose 13.98% year-over-year to $212000.0, compared with a TTM value of $212000.0 through Mar 2019, up 13.98%, and an annual FY2018 reading of $223000.0, up 112.38% over the prior year.
  • Other Accumulated Expenses was $212000.0 for Q1 2019 at Larimar Therapeutics, down from $223000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $292000.0 in Q1 2015 and bottomed at $56000.0 in Q3 2016.
  • Average Other Accumulated Expenses over 5 years is $146235.3, with a median of $119000.0 recorded in 2015.
  • The sharpest move saw Other Accumulated Expenses tumbled 63.36% in 2016, then surged 140.0% in 2018.
  • Year by year, Other Accumulated Expenses stood at $161000.0 in 2015, then tumbled by 31.68% to $110000.0 in 2016, then dropped by 4.55% to $105000.0 in 2017, then surged by 112.38% to $223000.0 in 2018, then fell by 4.93% to $212000.0 in 2019.
  • Business Quant data shows Other Accumulated Expenses for LRMR at $212000.0 in Q1 2019, $223000.0 in Q4 2018, and $180000.0 in Q3 2018.